Lys Therapeutics

Executive Summary

Lys Therapeutics is a French biotechnology company founded in 2018 and headquartered in Paris, focused on developing first-in-class biotherapies for neurological diseases. The company's innovative platform targets dysfunction of the blood-brain barrier (BBB) as a root cause of neuroinflammation and neurodegeneration. Its lead candidate, LYS241, is a monoclonal antibody designed to restore BBB integrity without needing to cross into the brain, offering a novel approach to treating conditions such as multiple sclerosis, Alzheimer's disease, and stroke. Currently in preclinical development, Lys Therapeutics has the potential to address significant unmet medical needs by modulating the BBB, a pathway that has been largely unexplored by other therapies. The company's strategy leverages proprietary antibody engineering to selectively target components of the BBB, aiming to reduce neuroinflammation and protect neuronal function. As a private entity, Lys Therapeutics has not disclosed funding details but continues to advance its pipeline towards clinical trials. The novelty of its mechanism and the high prevalence of BBB-related neurological disorders position it as an intriguing candidate for future partnerships and investment.

Upcoming Catalysts (preview)

• Q3 2026Publication of preclinical efficacy data in peer-reviewed journal70% success
• Q2 2027Completion of IND-enabling studies and regulatory filing40% success
• TBDStrategic partnership or licensing deal30% success